Trials / Completed
CompletedNCT04766398
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
A Phase 3, Randomized, Double-blind, Placebo-controlled, Phosphate Binder-combination, Parallel-group Comparative Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 169 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in combination with phosphate binders for 6 weeks and those receiving placebo in combination with phosphate binders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK7791 | oral administration |
| DRUG | Placebo | oral administration |
Timeline
- Start date
- 2021-03-15
- Primary completion
- 2021-09-27
- Completion
- 2021-09-27
- First posted
- 2021-02-23
- Last updated
- 2021-10-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04766398. Inclusion in this directory is not an endorsement.